Pharma stocks bounced back on November 25, ending a three-session losing streak and lifting the Nifty Pharma index into positive territory. The overall sentiment improved after a fresh brokerage note from Jefferies turned the spotlight on Lupin, which emerged as the top gainer on the index.<\/p>\n
By 12:05 pm, the Nifty Pharma index was up 0.74%, trading near 22,660. This relief rally came after three consecutive days of decline, offering some stability to investors tracking the sector.<\/p>\n
Shares of several leading pharmaceutical companies moved higher, with multiple heavyweights contributing to the index\u2019s recovery.<\/p>\n
Lupin was the strongest performer on the index.<\/p>\n
Lupin<\/a> shares surged over 2%, trading at \u20b92,047 apiece.<\/p>\n<\/li>\n The stock gained momentum after Jefferies reiterated its \u2018Buy\u2019 rating with a target price of \u20b92,300.<\/p>\n<\/li>\n This target signals an upside potential of over 15% from the previous close.<\/p>\n<\/li>\n<\/ul>\n Jefferies highlighted that the biosimilars segment is poised to become the next major growth engine for Lupin, which boosted investor confidence around the stock.<\/p>\n Several major pharma companies joined the uptrend:<\/p>\n Glenmark Pharma<\/a>, Dr. Reddy\u2019s Laboratories<\/a>, and Aurobindo Pharma<\/a> gained nearly 2% each.<\/p>\n<\/li>\n Cipla <\/a>rose over 1%, while IPCA Laboratories,<\/a> Zydus Lifesciences<\/a>, and Torrent Pharma <\/a>were up nearly 1%.<\/p>\n<\/li>\n<\/ul>\n Other notable names, such as JB Chemicals, Mankind Pharma, Sun Pharma, Laurus Labs, Divi\u2019s Labs, and Ajanta Pharma, traded in the green with marginal gains.<\/p>\n However, not all stocks participated in the rebound. Dr. Reddy\u2019s Laboratories also attracted attention, rising more than 1% after the company received a significant regulatory approval.<\/p>\n The European Commission (EC) granted marketing authorization for AVT03, a biosimilar of Prolia (denosumab) and Xgeva (denosumab).<\/p>\n<\/li>\n These drugs are widely used for managing osteoporosis and bone complications associated with cancer.<\/p>\n<\/li>\n<\/ul>\n A biosimilar, being a replica of a high-cost biological medicine, offers a more affordable treatment option in global markets.<\/p>\n Dr. Reddy\u2019s highlighted details of its licensing and supply agreement:<\/p>\n In May 2024, the company partnered with Alvotech for AVT03 commercialization.<\/p>\n<\/li>\n Alvotech will handle development and manufacturing, while Dr. Reddy\u2019s will manage registration and commercialization in the U.S., Europe, and other markets.<\/p>\n<\/li>\n Dr. Reddy\u2019s has exclusive rights in the U.S. and semi-exclusive rights in Europe and the UK.<\/p>\n<\/li>\n Upon approval, the biosimilar will be marketed under the brand names Acvybra and Xbonzy in respective dosage forms.<\/p>\n<\/li>\n<\/ul>\n Despite today\u2019s uptick, Dr. Reddy\u2019s share performance has been mixed:<\/p>\n The stock has fallen over 3% in the past month.<\/p>\n<\/li>\n It has made marginal gains over the past six months.<\/p>\n<\/li>\n For the 2025 year-to-date, the stock is down more than 9%.<\/p>\n<\/li>\n However, over the past five years, it has risen 29%.<\/p>\n<\/li>\n<\/ul>\n The rebound in pharma stocks reflects renewed optimism in the sector after a brief period of weakness. With brokerages reiterating positive views, regulatory tailwinds, and selective stock-specific developments, market sentiment appears to be stabilizing.<\/p>\n Click here to explore:<\/strong><\/em> Pharma stocks bounced back on November 25, ending a three-session losing streak and lifting the Nifty Pharma index into positive territory. The overall sentiment improved after a fresh brokerage note from Jefferies turned the spotlight on Lupin, which emerged as the top gainer on the index. Nifty Pharma Index Rises After Recent Weakness By 12:05 […]<\/p>\n","protected":false},"author":7,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[615],"tags":[],"ppma_author":[1384],"class_list":{"0":"post-18045","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-stock-market-news"}," _eael_post_view_count":0,"authors":[{"term_id":1384,"user_id":7,"is_guest":0,"slug":"jitesh-kanwariya","display_name":"Jitesh Kanwariya","avatar_url":{"url":"https:\/\/trending.niftytrader.in\/wp-content\/uploads\/2025\/08\/Jitesh-Kanwriya.jpeg","url2x":"https:\/\/trending.niftytrader.in\/wp-content\/uploads\/2025\/08\/Jitesh-Kanwriya.jpeg"},"0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":""}],"_links":{"self":[{"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/posts\/18045","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/comments?post=18045"}],"version-history":[{"count":1,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/posts\/18045\/revisions"}],"predecessor-version":[{"id":18047,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/posts\/18045\/revisions\/18047"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/media\/18046"}],"wp:attachment":[{"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/media?parent=18045"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/categories?post=18045"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/tags?post=18045"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/ppma_author?post=18045"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Broad-Based Gains Across Pharma Counters<\/h2>\n
\n
Alkem Laboratories, Biocon, Piramal Pharma, Abbott India, Gland Pharma, and Wockhardt slipped up to 1%, bucking the broader trend.<\/p>\nRegulatory Boost for Dr. Reddy\u2019s<\/h2>\n
\n
\n
Dr. Reddy\u2019s Stock Performance<\/h2>\n
\n
Sector Outlook Turns Positive<\/h3>\n
\nGift Nifty<\/a>
\nFII DII Data<\/a>
\nIPO<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"